Pyoderma gangrenosum: Pathogenetic oriented treatment approaches

Wiener Medizinische Wochenschrift

Volumn 164, Issue 13-14, 2014, Pages 263-273

  Wollina, Uwe ^a   Tchernev, Georgi ^b  

^a ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^b UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

Author keywords

IL 1 inhibitors; Inflammasome; Neutrophilic disorders; Pyoderma gangrenosum; TNF inhibitors

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AZATHIOPRINE; CANAKINUMAB; CLOFAZIMINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; ETANERCEPT; GEFITINIB; INFLAMMASOME; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ISOTRETINOIN; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PROPYLTHIOURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SULPIRIDE; SUNITINIB; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; CYTOSKELETON PROTEIN; INTERLEUKIN 1 RECEPTOR; PSTPIP1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; CLINICAL FEATURE; DISEASE EXACERBATION; GASTROINTESTINAL DISEASE; GENE; GENE MUTATION; HUMAN; HYPERPIGMENTATION; IMMUNOPATHOGENESIS; KIDNEY FAILURE; NEUROPATHY; PATHOGENESIS; PSTPIP1 GENE; PYODERMA GANGRENOSUM; REVIEW; TOPICAL TREATMENT; UNSPECIFIED SIDE EFFECT; WOUND DRESSING; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE SEQUENCE; PHYSIOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CYTOSKELETAL PROTEINS; DNA MUTATIONAL ANALYSIS; HUMANS; INFLAMMASOMES; INTERLEUKIN-1; MOLECULAR TARGETED THERAPY; PYODERMA GANGRENOSUM; RECEPTORS, INTERLEUKIN-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84906936314     PISSN: 00435341     EISSN: 1563258X     Source Type: Journal    
DOI: 10.1007/s10354-014-0285-x     Document Type: Review

References (100)

1. Brunsting LA, Goeckerman WH, O'Leary PA. Pyoderma [ecthyma] gangrenosum: Clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syph. 1930;22:655-80.
2. Tchernev G, Trebing D, Göring H-D, Steinhoff M, Zouboulis CC, Orfanos C. Pyoderma gangrenosum in Crohn's disease-the role of immunologic parameters and histological data in diagnosis and differential diagnosis. Bulg J Hepatogastroenterol. 2005;7:56-60.
3. Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol. 2002;3:149-58. (Pubitemid 34533775)
4. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25:469-84. doi: 10.1016/j.smim.2013.10.008.
5. Lipsker D, Lenormand C. Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases. Ann Dermatol Venereol. 2012;139:459-67.
6. Kowalzick L, Bertolini J, Baumann C, Walther B, Truhm B, Eickenscheidt L. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis. J Dtsch Dermatol Ges. 2013;11:447-9.
7. Kikuchi N, Hiraiwa T, Ohashi T, Hanami Y, Satoh M, Takenoshita H, et al. Pyoderma gangrenosum possibly triggered by adalimumab. Eur J Dermatol. 2012;22:804-5.
8. Stichenwirth M, Riedl E, Pehamberger H, Tappeiner G. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon? Arch Dermatol. 2008;144:817-8. (Pubitemid 351846899)
9. Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, Greebe RJ. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat. 2011;22:261-5.
10. Wollina U. Pyoderma gangrenosum - a review. Orphanet J Rare Dis. 2007;2:19.
11. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34:395-409. (Pubitemid 26083814)
12. Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2,402 patients. Medicine (Baltimore). 2008;87:281-93.
13. Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110-9.
14. Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012;132:2166-70.
15. Graham JA, Hansen KK, Rabinowitz LG, Esterly NB. Pyoderma gangrenosum in infants and children. Pediatr Dermatol. 1994;11:10-7. (Pubitemid 24085968)
16. Callen JP. Pyoderma gangrenosum and related disorders. Adv Dermatol. 1989;4:51-69.
17. Wolff K, Stingl G. Pyoderma gangrenosum. In: Freedberg IM, Eisen AZ, Wolff K, Austen FK, Goldsmith LA, Katz SI, et al., editors. Dermatology in general medicine. New York: McGraw Hill; 1999. pp. 1140-8.
18. Powell FC, Schroeter AL, Perry HO, Su WP. Direct immunofluorescence in pyoderma gangrenosum. Br J Dermatol. 1983;108:287-93. (Pubitemid 13152544)
19. Shaya S, Kindzelskii AL, Minor J, Moore EC, Todd RF 3rd, Petty HR. Aberrant integrin [CR4; αxβ2; CD11c/CD18] oscillation on neutrophils in a mild form of pyoderma gangrenosum. J Invest Dermatol. 1998;111:154-8. (Pubitemid 28309225)
20. Adachi Y, Kindzelskii AL, Cookingham G, Shaya S, Moore EC, Todd RF 3rd. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol. 1998;111:259-68. (Pubitemid 28354713)
21. Sams HH, Mitchell MM, Stratton CW, King LE Jr. Culture and immunohistochemical evidence of chlamydia infection in ulcerative pyoderma gangrenosum. J Am Acad Dermatol. 2003;48:966-9. (Pubitemid 36706239)
22. Braun-Falco M, Ruzicka T. Skin manifestations in autoinflammatory syndromes. J Dtsch Dermatol Ges. 2011;9:232-46.
23. Lamprecht P, Gross WL. Autoinflammatory syndromes. Internist (Berl). 2009;50:676-84.
24. Contassot E, Beer HD, French LE. Interleukin-1, inflammasomes, autoinflammation and the skin. Swiss Med Wkly. 2012;142:w13590.
25. Almeida de jA, Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol. 2013;147:155-74.
26. Wollina U, Haroske G. Pyoderma gangraenosum. Curr Opin Rheumatol. 2011;23:50-6.
27. Nesterovitch AB, Hoffman MD, Simon M, Petukhov PA, Tharp MD, Glant TT. Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum. Clin Exp Dermatol. 2011;36:889-95.
28. Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, Wise CA, et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A. 2003;100:13501-6. (Pubitemid 37444771)
29. Hara H, Tsuchiya K, Kawamura I, Fang R, Hernandez-Cuellar E, Shen Y, et al. Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat Immunol. 2013;14:1247-55.
30. Salminen A, Kauppinen A, Hiltunen M, Kaarniranta K. Epigenetic regulation of ASC/TMS1 expression: potential role in apoptosis and inflammasome function. Cell Mol Life Sci. 2014;71:1855-64.
31. Müller-Ladner U, Alten R, Heiligenhaus A, Kekow J, Koletzko S, Mrowietz U, et al. "TRECID", TNFalpha related chronic inflammatory diseases-a new multiple diseases bridging concept. Dtsch Med Wochenschr. 2009;134:2132-6.
32. Fellermann K. Adverse events of tumor necrosis factor inhibitors. Dig Dis. 2013;31:374-8.
33. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1-14.
34. Schadt CR, Callen JP. Management of neutrophilic dermatoses. Dermatol Ther. 2012;25:158-72.
35. Al Ghazal PH, Herberger K, Schaller J, Strölin A, Hoff NP, Goerge T, et al. Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis. 2013;8:136.
36. Powell F, Schroeter A, Su W, Perry H. Pyoderma gangrenosum: a review of 86 patients. Q J Med. 1985;55:173-86. (Pubitemid 15047362)
37. Seitz CS, Berens N, Bröcker EB, Trautmann A. Leg ulceration in rheumatoid arthritis - an underreported multicausal complication with considerable morbidity: analysis of thirty-six patients and review of the literature. Dermatology. 2010;220:268-73.
38. Hasegawa M, Nagai Y, Sogabe Y, Hattori T, Inoue C, Okada E, et al. Clinical analysis of leg ulcers and gangrene in rheumatoid arthritis. J Dermatol. 2013;40:949-54.
39. Chia HY, Tang MB. Chronic leg ulcers in adult patients with rheumatological diseases-a 7-year retrospective review. Int Wound J. 2012;doi: 10.1111/iwj.12012. [Epub ahead of print]
40. Wollina U, Hein G. Lupus erythematosus: uncommon presentations. Clin Dermatol. 2005;23:470-9. (Pubitemid 41338380)
41. Reddy V, Dziadzio M, Hamdulay S, Boyce S, Prasad N, Keat A. Lupus and leg ulcers-a diagnostic quandary. Clin Rheumatol. 2007;26:1173-5. (Pubitemid 46863972)
42. Feld J, Bergman R, Weltfriend S, Zisman D. Pyoderma gangrenosum in a patient with systemic sclerosis. J Rheumatol. 2012;39:197.
43. Fujikura M, Ohtsuka T, Oyamada Y. Systemic sclerosis in association with peristomal pyoderma gangrenosum. Br J Dermatol. 2007;157:618-9. (Pubitemid 47256103)
44. Shah M, Lewis FM, Harrington CI. Scrotal pyoderma gangrenosum associated with dermatomyositis. Clin Exp Dermatol. 1996;21:151-3. (Pubitemid 26227953)
45. Zycinska K, Wardyn K, Zielonka TM, Nitsch-Osuch A, Smolarczyk R. Cutaneous changes: an initial manifestation of pulmonary Wegener's granulomatosis. Adv Exp Med Biol. 2013;755:307-10.
46. Halac U, Al Dhaybi R, Powell J, Bouron-Dal Soglio D, Alvarez F. Unusual association between autoimmune hepatitis and severe pyoderma gangrenosum. J Pediatr Gastroenterol Nutr. 2010;50:219-21.
47. Chandrasekhara PK, Jayachandran NV, Thomas J, Agrawal S, Narsimulu G. Successful treatment of pyoderma gangrenosum associated with juvenile idiopathic arthritis with a combination of topical tacrolimus and oral prednisolone. Clin Rheumatol. 2009;28:489-90.
48. Ravic-Nikolic A, Milicic V, Ristic G, Jovovic-Dagovic B. Pyoderma gangrenosum associated with Sjögren syndrome. Eur J Dermatol. 2009;19:392-3.
49. Richetta AG, D'Epiro S, Mattozzi C, Giancristoforo S, Calvieri S. Folgoration as an example of pathergy in a patient affected by pyoderma gangrenosum and Takayasu's arteritis. Dermatol Res Pract. 2009;2009:393452.
50. Dejardin Botelho A, Delesalle F, Delaporte E, Wallaert B. Pyoderma gangrenosum and Churg-Strauss syndrome. Rev Med Interne. 2007;28:564-5.
51. Mehta AJ, Charman CR. Pyoderma gangrenosum in association with autoimmune neutropenia of infancy. Pediatr Dermatol. 2008;25:620-2.
52. Coors EA, von den Driesch P. Pyoderma gangrenosum in a patient with autoimmune haemolytic anaemia and complement deficiency. Br J Dermatol. 2000;143:154-6. (Pubitemid 30485260)
53. Necas M, Semrádova V, Vaskù V. Pyoderma gangraenosum associated with autoimmune thyreopathy and hyperandrogenic syndrome. Acta Dermatovenerol Alp Panonica Adriat. 2005;14:57-60. (Pubitemid 40942271)
54. Livideanu C, Lipsker D, Paul C, Juillard J, Schubert B. Pyoderma gangrenosum as initial manifestation of Graves' disease. Clin Exp Dermatol. 2006;31:659-61. (Pubitemid 44086793)
55. Matis WL, Ellis CN, Griffiths CEM, Lazarus GS. Treatment of pyoderma gangrenosum with cyclosporin. Arch Dermatol. 1992;128:1060-4.
56. O'Donnell B, Powell FC. Cyclosporin treatment of pyoderma gangrenosum. J Am Acad Dermatol. 1991;24:141-3.
57. Zumdick M, Goerz G, Schuppe HC, Milde P, Ruzicka T. Niedrig dosierte Cyclosporin-A-Therapie bei Pyoderma gangraenosum. Erfahrungen bei 6 Patienten. Hautarzt. 1995;46:697-701.
58. Van den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137:1000-5.
59. Prystowsky JH, Kahn SN, Lazarus GS. Present status of pyoderma gangrenosum. Arch Dermatol. 1989;125:57-64.
60. Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol. 1995;32:241-7.
61. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs. 2000;60:273-92.
62. Wollina U, Karamfilov T. Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. J Eur Acad Dermatol Venereol. 2000;14:187-90. (Pubitemid 32899293)
63. Daniels NH, Callen JP. Mycophenolate mofetil is an effective treatment for peristomal pyoderma gangrenosum. Arch Dermatol. 2004;140:1427-9. (Pubitemid 39627432)
64. Lee MR, Cooper AJ. Mycophenolate mofetil in pyoderma ganrenosum. J Dermatolog Treat. 2004;15:303-7.
65. Baumgart DC, Wiedenmann B, Dignass AU. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus [FK506] in ulcerative colitis. Inflamm Bowel Dis. 2004;10:421-4. (Pubitemid 39029185)
66. Kontochristopoulos GJ, Stavropoulos PG, Gregoriou S, Zakopoulou N. Treatment of pyoderma gangrenosum with low-dose colchicine. Dermatology. 2004;209:233-6. (Pubitemid 39370335)
67. Schmidt C, Wittig BM, Moser C, Zeitz M, Stallmach A. Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn's disease. Aliment Pharmacol Ther. 2006;24:343-50. (Pubitemid 43972902)
68. Budde K, Glander P, Diekmann F, Waiser J, Fritsche L, Dragun D, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother. 2004;5:1333-45. (Pubitemid 38885793)
69. Fujimoto E, Fujimoto N, Kuroda K, Tajima S. Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol. 2004;151:1090-2. (Pubitemid 39573902)
70. Mori S, Nagashima M, Yoshida K, Yoshino K, Aoki M, Kawana S, et al. Granulocyte adsorptive apheresis for leg ulcers complicated by rheumatoid arthritis: a report on three successfully treated cases. Int J Dermatol. 2004;43:732-5. (Pubitemid 39405856)
71. Girolomoni G, Pastore S, Albanesi C, Cavani A. Targeting tumor necrosis factor-alpha as a potential therapy in inflammatory skin diseases. Curr Opin Investig Drugs. 2002;3:1590-5. (Pubitemid 36266732)
72. Mimouni D, Anhalt GJ, Kouba DJ, Nousari HC. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol. 2003;148:813-6. (Pubitemid 36629765)
73. Sapienza MS, Cohen S, Dimarino AJ. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci. 2004;49:1454-7. (Pubitemid 39273621)
74. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int. 2005;25:406-10. (Pubitemid 41186906)
75. Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol. 2006;54(Suppl 2):128-34.
76. Hinterberger L, Müller CS, Vogt T, Pföhler C. Adalimumab: a treatment option for pyoderma gangrenosum after failure of systemic standard therapies. Dermatol Ther (Heidelb). 2012;2(1):6.
77. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10:89-102.
78. Steiger S, Harper JL. Mechanisms of spontaneous resolution of acute gouty inflammation. Curr Rheumatol Rep. 2014;16:392.
79. Tavares AH, Magalhães KG, Almeida RD, Correa R, Burgel PH, Bocca AL. NLRP3 Inflammasome activation by Paracoccidioides brasiliensis. PLoS Negl Trop Dis. 2013;7:e2595.
80. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39:1003-18.
81. Cunha LD, Zamboni DS. Subversion of inflammasome activation and pyroptosis by pathogenic bacteria. Front Cell Infect Microbiol. 2013;3:76.
82. Mao L, Zhang L, Li H, Chen W, Wang H, Wu S, et al. Pathogenic fungus Microsporum canis activates the NLRP3 inflammasome. Infect Immun. 2014;82:882-92.
83. Miao EA, Leaf IA, Treuting PM, Mao DP, Dors M, Sarkar A, et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol. 2010;11:1136-42.
84. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161:1199-201.
85. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409-15.
86. Baumgart DC, Wiedenmann B, Dignass AU. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus [FK506] in ulcerative colitis. Inflamm Bowel Dis. 2004;10:421-4. (Pubitemid 39029185)
87. Khurrum Baig M, Marquez H, Nogueras JJ, Weiss EG, Wexner SD. Topical tracrolimus [FK506] in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn's disease: report of two cases. Colorectal Dis. 2004;6:250-3. (Pubitemid 38960852)
88. Wollina U. Letter to the editor: Temporary renal insufficiency associated with topical tacrolimus treatment of multilocal pyoderma gangrenosum. J Dermatol Case Rep. 2013;7:106-7.
89. Neiderer K, Martin B, Hoffman S, Jolley D, Dancho J. A mechanically powered negative pressure device used in conjunction with a bioengineered cell-based product for the treatment of pyoderma gangrenosum: a case report. Ostomy Wound Manage. 2012;58:44-8.
90. Hill DS, O'Neill JK, Toms A, Watts AM. Pyoderma gangrenosum: a report of a rare complication after knee arthroplasty requiring muscle flap cover supplemented by negative pressure therapy and hyperbaric oxygen. J Plast Reconstr Aesthet Surg. 2011;64:1528-32.
91. Ghersi MM, Ricotti C, Nousari CH, Newman MI. Negative pressure dressing in the management of pyoderma gangrenosum ulcer. Arch Dermatol. 2007;143:1249-51. (Pubitemid 47607692)
92. Mir-Bonafé JM, Blanco-Barrios S, Romo-Melgar A, Santos-Briz A, Fernández-López E. Photoletter to the editor: Localized pyoderma gangrenosum after interferon-alpha2b injections. J Dermatol Case Rep. 2012;6:98-9.
93. ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib? Br J Dermatol. 2008;159:242-3. (Pubitemid 351874484)
94. Nadauld LD, Miller MB, Srinivas S. Pyoderma gangrenosum with the use of sunitinib. J Clin Oncol. 2011;29:e266-7.
95. Sagara R, Kitami A, Nakada T, Iijima M. Adverse reactions to gefitinib (Iressa): revealing sycosis- and pyoderma gan-grenosum-like lesions. Int J Dermatol. 2006;45:1002-3. (Pubitemid 44145053)
96. Bustillo I, Kaley K, Saif MW. Rash associated with the use of pegylated filgrastim in a patient with advanced pancreatic cancer. Cutan Ocul Toxicol. 2009;28:181-4.
97. Tinoco MP, Tamler C, Maciel G, Soares D, Avelleira JC, Azulay D. Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic. Int J Dermatol. 2008;47:953-6.
98. Freiman A, Brassard A. Pyoderma gangrenosum associated with isotretinoin therapy. J Am Acad Dermatol. 2006;55:107-8.
99. Hong SB, Lee MH. A case of propylthiouracil-induced pyoderma gangrenosum associated with antineutrophil cytoplasmic antibody. Dermatology. 2004;208:339-41.
100. Srebrnik A, Shachar E, Brenner S. Suspected induction of a pyoderma gangrenosum-like eruption due to sulpiride treatment. Cutis. 2001;67:253-6. (Pubitemid 33756266)